Hemispherx Biopharma to study Alferon against Tamiflu resistant influenza virus strains
It will now be evaluated against wild type and Tamiflu (oseltamivir)-resistant H7N9 influenza virus under the DEA (Data Exchange Agreement) Annex for Medical Preparedness and Bio-Defense Agreement between
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.